---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029413"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T18:59:17.115922+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical shareholders re-elect all three director nominees

## Summary
- Jeffrey L. Edwards, Clay B. Thorp, and Benjamin R. Yerxa re-elected with 21.0M, 21.0M, and 22.8M votes for, respectively.
- Advisory vote on executive compensation passed with 21.9M for, 1.0M against, 2.3M abstain.
- Ratification of Ernst & Young as auditor for FY 2023 approved (40.2M for, 0.1M against).
- Turnout: 40.7M shares (65.98%) of 61.7M outstanding present or represented.

## SEC filing metadata
- accession: 0000950170-23-029413
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/0000950170-23-029413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/clsd-20230622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029413
- JSON: https://secwatch.observer/filing/0000950170-23-029413.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029413.txt

## Key facts
- Shareholder Votes
  Clearside Biomedical, Inc. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Jeffrey L. Edwards 21,010,493 4,195,234 Clay B. Thorp 21,038,323 4,167,404 Benjamin R. Yerxa 22,824,670 2,381,057 Broker Non-Votes: 15,481,349. All nominees were elected.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/0000950170-23-029413-index.htm
- Shareholder Votes
  Clearside Biomedical, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 3 : Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Ernst & Young LLP 40,223,369 118,934 344,773
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/0000950170-23-029413-index.htm
- Shareholder Votes
  Clearside Biomedical, Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. at the 2023-06-22 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation paid to the named executive officers 21,869,683 1,039,147 2,296,897 Broker Non-Votes: 15,481,349.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023029413/0000950170-23-029413-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.